Phaco after trab may increase bleb failure rates at 1 year, but not 2 years

Article

Phacoemulsification done after trabeculectomy may significantly increase the rates of bleb failure in the following 12 months, but not at 24 months, according to a recently published study.

Phacoemulsification done after trabeculectomy may significantly increase the rates of bleb failure in the following 12 months, but not at 24 months, according to a recent study published in Clinical & Experimental Ophthalmology.

For this retrospective case control study, Dan Q Nguyen, FRCOphth, and fellow researchers at the University of Melbourne and the Royal Victorian Eye & Ear Hospital, Melbourne, Australia, included 48 patients who had undergone trabeculectomy and ≥2 years of follow-up. Patients were classified into two groups: those who had phacoemusification subsequent to trabeculectomy (trab_phaco; n = 18), and those who were pseudophakic for >6 months preceding trabeculectomy (Phaco_trab; n = 30). These groups were matched for length of follow-up of 2 years from time of trabeculectomy.

Researchers found no significant differences between the groups in achieving the primary outcome measures of target IOP of criteria A ≤12 mmHg, criteria B ≤15 mmHg, or criteria C ≤18 mmHg with or without additional topical treatment at 12 months (P = 1.0) and at 24 months (P = 0.330). In the first 12 months, significantly more trabeculectomies failed in the Trab_phaco group and required additional intervention for IOP control compared with the Phaco_trab group (39% vs 10%; P = 0.028). This trend continued at 24 months, but no significant differences in failure rates were seen between the groups (P = 0.522).

To access this study, go to the journal's website.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.